healthcare

The UK’s MHRA is accelerating the evaluation of AI tools to revolutionize healthcare, aiming to drastically reduce medical test result waiting times through its ‘AI Airlock’ program. Seven novel AI technologies are being rigorously assessed to address healthcare challenges, potentially speeding up cancer diagnosis and improving detection of genetic eye diseases. The program provides a secure environment for testing, informing the MHRA’s evolving AI regulatory framework and the National Commission into the Regulation of AI in Healthcare. This initiative emphasizes safe and effective AI adoption within the NHS.

Mercy has received the NRC Health Excellence in Patient Experience Award for the fourth year running. The award, based on feedback from over 1.25 million patients, recognizes Mercy’s commitment to patient-centered care. Mercy emphasizes a holistic approach involving various staff roles in creating a positive experience. This award highlights the growing importance of patient experience in healthcare, as satisfaction impacts reputation and market share. Mercy shares patient survey data through NRC Health’s transparency program, building trust and improving patient retention.

Aetna, a CVS Health company, announced strong performance in its Medicare Advantage (MA) plans, with over 81% of members in plans rated 4 stars or higher by CMS for 2026; over 63% are in 4.5-star plans. Several Aetna contracts have consistently maintained or improved their high star ratings, reflecting Aetna’s commitment to quality care and member satisfaction. These ratings are crucial for member choice and impact plan reimbursement rates. Aetna leverages technology and integrated care to enhance offerings.

Retrieve Medical Holdings, Inc. is launching Retrieve Personal, a platform providing secure, immediate access to comprehensive medical records for patients and providers. Integrating with Health Information Exchanges (HIEs) and leveraging AI, Retrieve Personal compiles complete patient histories into actionable summaries. ID.me provides secure identity verification. This initiative addresses fragmented patient information but faces challenges like HIE interoperability and data standardization. The aim is portable health summaries, enhancing personalized healthcare and improving efficiency.

REGENXBIO (Nasdaq: RGNX) will participate in several investor conferences in September 2025, including events hosted by Wells Fargo, Morgan Stanley, Baird, and H.C. Wainwright. The company will engage in one-on-one meetings and fireside chats to discuss its strategic vision, clinical progress, and the potential of its AAV gene therapies for rare and retinal diseases, including RGX-202 for Duchenne muscular dystrophy and surabgene lomparvovec (ABBV-RGX-314) for wet AMD and diabetic retinopathy. Webcasts will be available on REGENXBIO’s website.

OpenAI has launched GPT-5, touted as a significant upgrade with expert-level performance in programming, mathematics, writing, healthcare, and visual perception. GPT-5 features an intelligent model, a deep reasoning engine, and a real-time router. Free and paid users will get access, with subscribers enjoying higher usage. GPT-5 demonstrates improvements in response time, accuracy, instruction following, and reduced hallucination. It excels in programming, creative writing, and healthcare. GPT-5 Pro surpasses o3-Pro for complex tasks, achieving state-of-the-art results in GPQA.

Weave (NYSE: WEAV) will release its Q2 2025 financial results on July 31, 2025, after market close. A conference call and webcast will follow at 4:30 p.m. ET, accessible via phone at (412) 902-1020 or (877) 502-7186, and online at investors.getweave.com. Weave provides SaaS solutions focusing on customer experience and payment processing for healthcare practices, aiming to streamline patient interactions and billing.

KellyOCG + Sevenstep received

Baxter International Inc. (BAX) declared a quarterly cash dividend of $0.17 per share, payable on October 1, 2025, to stockholders of record as of August 29, 2025. This establishes an indicated annual dividend rate of $0.68 per share. Baxter, a global medtech leader, provides a wide array of healthcare solutions. The release also contains cautionary statements regarding forward-looking financial projections and potential deviations in dividend payouts.

Please provide the content you would like me to summarize. I need the text to create a concise English abstract for it.